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Purpose: The role of specialized pharmacy services remains unexplored in clinical practice
for hepatitis C patients in Pakistan. This study aimed to evaluate the impact of clinical
pharmacy interventions on treatment outcomes, health-related quality of life (HRQoL), and
medication adherence among hepatitis C patients.
Methods: A randomized control trial was conducted at two tertiary-care teaching hospitals in
Pakistan. Hepatitis C patients who attended the outpatient clinics between October 2015 and
September 2018 were randomized to two groups [usual care (UC) and pharmaceutical care
(PC)] in a 1:1 ratio, applying simple envelope method. The PC group received pharmaceutical
care led by a clinical pharmacist. The care that patients received included education and counseling
on medication compliance, labeling of medication packs, and monitoring of adverse drug events,
led by a qualiﬁed clinical pharmacist during the 15- to 20-minute monthly sessions, while the UC
group received standard care at hospital, which did not involve clinical pharmacist input. Outcome
measures, such as sustained virological response, HRQoL, and adherence rate (pharmacy data)
were assessed at enrolment and distinct time intervals: 4 weeks, 8 weeks, and end of treatment.
Results: A total of 931 patients were included in the study (UC 466 and PC 465), with mean
age 42.35±1.9 years. Sustained virological response at 12 weeks was achieved in 86.0%
patients in the PC group, signiﬁcantly (p<0.001) higher than the UC (69.3%) group. Fewer
patients (9.9%) in the PC group reported mobility problems, signiﬁcantly fewer (p<0.001)
than the UC group (11.8%). Self-care, usual activity, pain, and depression were relieved
signiﬁcantly in the PC group compared to the UC group. The EuroQol visual analogue scale
(baseline 56.1 of UC group versus 55.2 for PC group) was raised to 71.8 and 71.9 in the UC
and PC groups, respectively. Medication adherence was signiﬁcantly improved (p<0.001) in
the PC group (88.6%) when compared to the UC group (77.9%, 95% CI 88.9%–91.9%).
Conclusion: Pharmacist-led clinical pharmacy interventions as part of multidisciplinary
care had a signiﬁcant impact on improving cure rates, HRQoL, and medication adherence for
hepatitis C patients. This study suggests that clinical pharmacists should be incorporated into
the multidisciplinary health-care team for care of hepatitis C patients.
Keywords: hepatitis C, clinical pharmacy, medication adherence, clinical outcomes, quality of life
Introduction
Hepatitis C virus (HCV) infection is a health-care problem worldwide.1 The esti-
mated global prevalence of HCV has been reported to be approximately 2.2%–3.0%
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(130–170 million people) in the literature.1–3 Recent
advances in HCV pharmacotherapies and the development
of a World Health Organisation HCV-elimination strategy
has resulted in a signiﬁcant increase in “test and treat”
programs.4–6 Novel direct acting antiviral (DAA)–based
therapies are effective in 95% of HCV patients.7 However,
long-term therapy with DAAs and pill burden often results
in nonadherence that leads to suboptimal treatment out-
comes in HCV patients.8–10
Although the major determinants of therapeutic response
to pharmacotherapy include HCV genotype and viral load,
additional factors, such as medication adherence and optimal
duration of treatment, contribute to therapeutic outcomes.11
Various studies have highlighted the signiﬁcance of educat-
ing patients to improve adherence and treatment outcomes,
including education on treatment schedules and side effects,
especially prior to initiation of antiviral therapy.12–14
The key element of effective HCV clinical management
is access to a multidisciplinary team (MDT).15 As a member
of a multidisciplinary team, the pharmacist is in an ideal
position to serve patients with chronic HCV, not only
through patient counseling regarding the disease state, ther-
apeutic regimen, and associated adverse events but also by
educating patients on the vital role of treatment adherence
in the achievement of optimal therapeutic outcomes.16
Pharmacist interventions and patient education on medica-
tion use have played a central role in improving adherence
and management of other chronic diseases.17,18 The
European Society for the Study of the Liver in 2018 also
emphasized the19,20 vital role of pharmacists in educating
patients on potential drug–drug interactions (DDIs) and
improving adherence to the treatment regimen that will
eventually result in signiﬁcant improvement in health-
related quality of life (HRQoL) for all patients receiving
HCV therapies.21
A recent comprehensive pharmaceutical care programme
in Spain demonstrated improved adherence and treatment out-
comes in HCV patients.22 A similar pilot study revealed that
safe and effective management of HCV infection can be
achieved through the involvement of clinical pharmacists in
patient care.23 Published studies have unveiled signiﬁcant
improvement in treatment outcomes as a consequence of
clinical pharmacist–led and person-centered care.24–26
Limited literature exists on the role of pharmacists in optimi-
zation of treatment regimens and management of adverse
effects in HCV infection,27 particularly in the context of low-
and middle-income countries (LMICs). LMICs harbour 80%
of the global HCV burden. Currently, Pakistan has
approximately 10 million HCV patients, and health-care sys-
tem is not fully equipped with clinical pharmacists specialized
in chronic HCV.28 Alongside this considerable burden, there is
limited literature on the context of beneﬁts of pharmacist
interventions within the infrastructure of health care in
LMICs among HCV patients being treated with new DAAs.
This study aimed to evaluate the impact of pharmacist-led
clinical interventions on treatment outcomes, HRQoL, and
medication adherence in HCV patients in Pakistan.
Methods
Study Design
A randomized control study was undertaken. The alloca-
tion ratio was 1:1.
Participants and Eligibility
Conﬁrmed HCV-positive patients aged ≥18 years who
presented to the gastroenterology department or HCV
clinic during the study period were eligible for inclusion
in the study. Those had been initiated on DAA treatment
[sofosbuvir (Sof), daclatasvir (Dac), or a combination
thereof with or without ribavirin (Rv)] and had given
informed consent were enrolled in the study. All patients
who were pregnant or coinfected with HBV, HDV, or
autoimmune hepatitis were excluded.
Patients were recruited from the outpatient clinic of
gastroenterology departments at two tertiary-care hospitals
in Islamabad and Lahore with a combined bed capacity of
2,346 (1,150 and 1,196 respectively). These hospitals have
dedicated pharmacies to dispense HCV medicines to
referred patients. The hospitals included in the study
accept referrals from primary- and secondary-care hospi-
tals, as well as basic health-care units situated in remote
areas of Pakistan. This study was conducted between
October 2015 and September 2018. Patients were divided
into two groups [usual care (UC) and pharmaceutical care
(PC)]. Written consent was obtained from each recruited
patient, and all patients had the purpose and conduct of the
study explained to them. Any queries raised by patients
were addressed to satisfy each recruited subject.
Usual Care (Control)
This group was given usual care by the hospital staff, which
included the input of physicians, a nurse, and/or pharmacy
technician. They were treated in accordance with the routine
clinical practices of hospital, which include diagnosis, dis-
pensing/issuance of medication by hospital-pharmacy staff,
Ali et al Dovepress
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and routine follow-up of patients at the health-care facility.
They did not receive interventions from the pharmacist.
These patients were provided guidance as per their require-
ments, and were not bound to attend any pharmacists' coun-
seling session. Hospital staff were also informed to refer their
patients to a pharmacist for any additional medicine–related
information or guidance.
Pharmaceutical Care (Interventional)
In addition to usual care, all the patients in the PC group were
provided with individualized patient care provided by a
clinical pharmacist. The additional care provided by the
pharmacist included direct patient monitoring, education on
lifestyle modiﬁcations, and counseling on the appropriate use
of HCV medication. All patients who consented to the phar-
macist’s counseling session were enrolled at baseline and
followed up until 12 weeks after the end of treatment. Each
patient was instructed to report to the pharmacist every
month during his/her visit for routine checkup by the physi-
cian. Clinical pharmacy services continued until treatment
completion. Moreover, patients were asked to inquire any
information pertaining to the medication by telephone after
the end of treatment.
Patients’ Pharmaceutical Care and
Interventions
Individualized patient care comprised the following:
1. Pharmacist counseling (15- to 20-minute sessions)
on the proper use of medication and the provision of
an educational pack inclusive of medication diary, a
laboratory proﬁle book, and a medication-adherence
chart.
2. Labeling of medication packs to assist pill sorting.
Labels included instructions on dose and frequency/
timing of medication doses.
3. Patient education using both oral and written
approaches. This protocol included an educational
leaﬂet pertaining to medicine administration, medi-
cine storage, and lifestyle modiﬁcation.
4. Detection or assessment of potential DDIs by a
pharmacist prior to start of treatment and recom-
mendations for their management.
5. Pharmacist counseling on the safe use of medication
(self-medication or over-the-counter [OTC] medi-
cines), monitoring, and prompt detection of adverse
drug events (ADEs).
A trained pharmacist provided the interventions described at
each health-care facility, along with the existing pharmacy
staff during the study period. The educational materials were
delivered in Urdu (local language). The pharmacist was
responsible for monitoring adherence to the HCV treatment.
Patients were interviewed at their ﬁrst visit and follow-up
visit each month in a dedicated room adjacent to the gastro-
enterologist's ofﬁce. Information pertaining to medicine
usage, missed doses/adherence, hematology and biochemis-
try data, incidence of any ADE, and evaluation of clinical
outcomes was retrieved from patients. Medication usage and
missed doses were monitored by retrieving the empty blister
packs of medicines from the patients in the pharmacy area,
followed by a pill count.27 Additionally, dose charts (ﬁlled)
were retrieved from the patients. Any missing information
was requested verbally from the patient. A separate roomwas
availed for patients’ counseling sessions and interviews and
to avoid any contamination with the UC group. The clinical
pharmacist had no access to or was not involved in the care of
the patients in the UC arm. To maintain the ethical role of
health-care provision, at the end of the study all patients who
attended the gastroenterology clinic after screening were
provided with an educational booklet containing information
on preventive care for family members.
Outcome Measures
The primary outcome measure was sustained virological
response at week 12 posttreatment (SVR12),29,30 while
secondary outcome measures were assessment of number
of ADEs, HRQoL, and medication adherence.
Sustained Virological Response
Clinical outcomes were assessed based on HCV viral load
measured at baseline, end of treatment, and 12 weeks after
the end of treatment (SVR12). A viral load of <12 IU/mL
at 12 weeks after the end of treatment was considered
undetectable and regarded as “cure”.31 HCV RNA levels
were measured using an Abbott m2000 real-time HCV
assay. Samples were sent to allied laboratories of these
hospitals for reporting of quantitative viral loads through
PCR. Data were extracted from the medical records of
patients for this parameter.
Adverse Drug Events, DDIs, and
Concomitant Medicines
The incidence of ADEs was assessed by trained pharmacist
based on the Common Terminology Criteria for Adverse
Dovepress Ali et al
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Events version 4.32 Data pertaining to ADEs were collected
at three time intervals: 4 weeks, 8 weeks, and 12 weeks from
the start of treatment in both arms. Assessment of clinical
potential DDIs, as well as recommendations for DDI man-
agement, were made in accordance with the Drug Interaction
Checker, University of Liverpool (http://www.hep-druginter
actions.org). The number and type of concomitant medica-
tions used was assessed based on the previously published
literature19 and 73rd edition of the British National
Formulary.
Health-Related Quality of Life
HRQoL was assessed at three time points: before, during, and
after treatment (at day 1, 8th week, and 12th week (end of
treatment). A validated tool (EuroQol 5D-3L) was adminis-
tered by the researcher during the patient’s visit to the phar-
macy. The EQ-5D-3L consists of ﬁve dimensions: mobility,
self-care, usual activity, pain/discomfort, and anxiety/depres-
sion. These dimensions were dichotomized into two levels for
analysis, ie, patient has no/mild problems (level 1) and patient
has moderate/severe problems (level 2). The EQ VAS records
the patient’s self-rated health on a scale numbered from 0
(worst perceived health) to 100 (best perceived health).33
Medication Adherence
Medication adherence was measured using data of pharmacy
reﬁlls (obtained from the pharmacy database). Pharmacy
reﬁlls were recorded at patients' hospital visits each month.
Data relating to adherence was collected at three time inter-
vals: 4 weeks, 8 weeks, and 12 weeks from the start of
treatment. The total number of pharmacy reﬁlls attended by
each patient divided by the number of advised reﬁlls by 100
was the algorithm used to calculate 34,35 Finally, adherence
was measured as the proportion of patients who had taken at
least 80% of their prescribed doses. The metric was used as
an approximation of the 80/80/80 rule. This rule refers to the
greater possibility of successful treatment outcome that is
associated with taking 80% Sof and 80% Rv for 80% of the
prescribed treatment duration.35
Sample Size
Based on the prevalence of HCV infection and sample size
that has been reported in the literature,24,36 we estimated a
minimum sample size of 384 from each center (95% CI with
conﬁdence interval 5%). The target sample size from the two
health-care facilities was 922, taking into account a potential
20% dropout rate. SVR12 was the major outcomemeasure to
assess the success of treatment and power analyses.
Randomization
Enrolled patients were randomized at a ratio of 1:1 using a
simple envelope method with modiﬁcation.37 Brieﬂy, the
physician at the time of ﬁrst visit/diagnosis picked one of
the envelopes marked UC or PC alternately, which was the
assigned to patients.36,37 A separate room was availed for
patients’ counseling sessions and interviews and to avoid
any contamination with the UC group. The pharmacist had
no access to or was not involved in the care of patients in
the UC arm. The principal investigator (TR) was respon-
sible for checking the pharmacists to assure the delivery of
all components of the interventions as intended.
Data Sources and Collection
Patient demographics and treatment variables were col-
lected on a predesigned data sheet moderated by the
research team, which consisted of a senior medical con-
sultant, a specialist pharmacist, and a statistician. Data
extraction was carried out by the principal investigator
and validated by the gastroenterologist. Variables were
age, sex, HCV genotype, HCV viral load, liver-health
status, presence of comorbidities, concomitant medication,
baseline hematology and biochemistry data, and treatment
regimens. During follow-up visits (at weeks 4, 8, and 12),
each variable wwas re-recorded to assess any changes.
The information was obtained from patients' proﬁles and
electronic records available via the hospital database and the
logistics management and information system. All data were
anonymized by the data collector prior to analysis by the
research team. Data sets were stored on a password-protected
computer at the Department of Pharmacy, Quaid-i-Azam
University, Islamabad, Pakistan. The necessary ethical
approvals were obtained from the Ethical Review Board of
PIMS Hospital Islamabad (F.1-1/2015/ERB/SZABMU),
SIMS (IRB/2017/333/SIMS), and the Bioethics Committee
of Quaid-i-Azam University, Islamabad (DFBS/2015-248).
All questionnaires or tools were adopted after the necessary
permissions from the corresponding organizations or the
authors.
Statistical Analysis
Statistical analyses were performed using SPSS version
24. Frequency distribution and descriptive statistics were
calculated for demographics. Results are reported in terms
of differences between groups with 95% CIs where appro-
priate. Pearson's χ2 was applied to compare demographic
and end-point variables. Mann–Whitney U tests were
Ali et al Dovepress
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conducted to compare groups. McNemar's χ2 was used to
analyze whether changes in percentage HRQoL between
the PC group and UC group were4 signiﬁcant.38 Missing
data were analyzed by missing-value analysis with SPSS
and any missing values replaced by mean values. p≤0.05
was taken as statistically signiﬁcant.
Results
Overall, 1,050 patients were enrolled. Of those, 931 were
eligible for randomization postscreening (n=757 from hospi-
tal A and n=174 from hospital B), while 119 were excluded.
All patients consented to take part. Patients were assigned to
one of the two groups (UC, n=466; PC, n=465). The mean-
age of patients was 42.35±1.9 years. There were 418 (44.9%)
males and 513 (55.1%) female s. Of the total cohort, 671
(72.1%) were urban residents. A total of 109 (11.7%) were
cirrhotic, and genotype 3a the most prevalent genotype
(96.6%). There was no signiﬁcant difference between the
UC and PC groups (p=0.88) for baseline viral load; Table 1
and Figure 1).
[CONSORT diagram (Figure 1) to appear here]
The treatment regimen Sof/Rv was the most prescribed
for 608 (65.3%) patients, followed by Sof/Dac/Rv for 201
(21.5%) and Sof/Dac for 13.1%. Baseline characteristics of
patients and treatment regimens are summarized in Table 1.
Clinical Outcomes
A total of 400 (86.0%) patients in the PC group achieved
SVR12, signiﬁcantly (p<0.001) more than the UC group —
323 (69.3%). A total of 192 (20.6%) did not attend their
12-week posttreatment follow-up appointment (134 [28.8%]
UC group vs 58 (12.5%) PC group, p<0.001). Overall, 287
Table 1 Baseline Demographic and Clinical Characteristics of Study Population
All Patients (n=931) UC Group (n=466) PC Group (n=465)
Age, years Mean ± SD 42.35±1.9 42.85±1.7 41.84±1.7
<40 439 (47.15%) 213 (45.7%) 226 (48.6%)
41–60 439 (47.15%) 225 (48.3%) 214 (46.0%)
>60 53 (5.7%) 28 (6.0%) 25 (5.4%)
Sex Males 418 (44.9%) 215 (46.1%) 203 (43.7%)
Females 513 (55.1%) 251 (53.9%) 262 (56.3%)
Residence Urban 671 (72.1%) 329 (70.6%) 342 (73.6%)
Rural 260 (27.9%) 137 (29.4%) 123 (26.4%)
Liver-health status Cirrhotic 109 (11.7%) 47 (10.1%) 62 (13.3%)
Noncirrhotic 822 (88.3%) 419 (89.9%) 403 (86.7%)
Diagnosis HCV/CHC 905 (97.2%) 458 (98.3%) 447 (96.1%)
HCV + comorbidities 26 (2.8%) 8 (1.7%) 18 (3.8%)
Genotype Untypeable/mixed 8 (0.8%) 2 (0.4%) 6 (1.3%)
1/1a 9 (1.0%) 4 (0.9%) 5 (1.1%)
1b 4 (0.4%) 3 (0.6%) 1 (0.2%)
3a 899 (96.6%) 451 (96.8%) 448 (96.3%)
3b 11 (1.2%) 6 (1.3%) 5 (1.1%)
Treatment history Naïve 920 (98.8%) 459 (98.5%) 461 (99.1%)
Previously treated 11 (1.2%) 7 (1.5%) 4 (0.9%)
Viral load (baseline) Very low viremia 24 (2.6%) 13 (2.8%) 11 (2.4%)
Low viremia 22 (2.4%) 13 (2.8%) 9 (1.9%)
Moderate 287 (30.8%) 139 (29.8%) 148 (31.8%)
High viremia 275 (29.5%) 139 (29.8%) 136 (29.2%)
Positive 323 (34.7%) 162 (34.8%) 161 (34.6%)
Treatment choices Sof/Rv 608 (65.3%) 307 (65.9) 301 (64.7)
Sof/Dac/Rv 201 (21.5%) 98 (21.0) 103 (22.2)
Sof/Dac 122 (13.1%) 61 (13.1) 61 (13.1)
Abbreviations: HCV, hepatitis C virus; CHC, chronic hepatitis C; Sof, sofosbuvir; Rv, ribavirin; Dac, daclatasvir; UC, usual care; PC, pharmaceutical care.
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(30.8%) patients presentedwith amoderate baseline viral load.
At the end of treatment, 818 (87.9%) had achieved a response
showing viral load below the detectable level, while 16 (1.7%)
had failed to achieve a response (p=0.16). Viral clearance was
achieved in 723 (77.7%) patients at 12 weeks after the end of
treatment, ie, SVR12, while 16 (1.7%) failed to achieve
SVR12. Table 2 contains the clinical outcomes of both groups
included in the study.
Adverse Drug Events
Fewer patients (38 [8.2%]) experienced an ADE in the PC
group than the UC group (49 [10.5%]). Dyspepsia/
gastroesophageal reﬂux was the most frequent ADE (n=20
[3.8%] in UC and n=14 [2.9%] in PC), followed by anemia
(n=12 [2.5%] in UC and n=11 [2.4%] in PC) and fatigue
(1.5% and 1.3% inUC and PC groups, respectively; Figure 2)
Concomitant Medication and Drug-Drug
Interactions with DAAs
There were 52 (11.2%) patients in UC group and 47
(10.1%) in the PC group using OTC or regular medications
along with the DAAs. When assessed by the pharmacist, the
possibility of DDIs between DAAs and self-medicated OTC
Figure 1 Flow diagram showing patient recruitment and follow-up.
Abbreviation: EVR, end-of-treatment virological response; SVR, sustained virological response.
Ali et al Dovepress
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products was low: n=8 (1.7%) in the UC group and n=5
(1.1%) in the PC group. In the UC group, proton-pump
inhibitorss were the most frequent concomitant medications
(n=14), followed by multivitamins (n=10) and NSAIDs
(n=6), while in the PC group multivitamins (n=12) were
the most frequent concomitant medicines, followed by pro-
ton-pump inhibitors (n=11) and NSAIDs (n=8). Table 3
details the potential DDIs identiﬁed in the study.
Health-Related Quality of Life
Before treatment in the UC group, 51.5%, 24.2%, and 15.5%
patients reported problems in these dimensions, respectively.
These problems were alleviated signiﬁcantly (p<0.001) to
11.8%, 4.9%, and 5.8%, respectively, at the end of treatment.
In the PC group, baseline dimensions (52.9%, 27.3%, and
15.9%) were relieved signiﬁcantly (p<0.001) to 10.1%,
4.0%, and 4.1% respectively (p<0.001, Table 4).
Overall, 47.0% of patients reported moderate levels of
pain or discomfort at baseline that were relieved, and only
0.3% had a complaint of pain at the end of treatment. No
signiﬁcant difference (p>0.05) was observed with regard to
reduction in pain between the PC group (baseline 221
[47.5%], ﬁnal two [0.4%])] and the UC group (baseline 217
[46.6%], ﬁnal three [0.6%]). However, McNemar's χ2
Table 2 Comparison of Outcome Parameters (Adherence and Clinical Outcomes) Among Groups
Outcomes Subcategories All Patients
(n=931)
n(%)
UC Group
(n=466)
n(%)
PC Group
(n=465)
n(%)
p-value (UC vs
PC)
ETR ETR (NA) 97 (10.4%) 57 (12.2%) 40 (8.6%)
Failed at ETR 16 (1.7%) 9 (1.9%) 7 (1.5%)
ETR achieved 818 (87.9%) 400 (85.8%) 418 (89.9%) 0.163
SVR12 Did not have SVR 192 (20.6%) 134 (28.8%) 58 (12.5%)
Failed 16 (1.7%) 9 (1.9%) 7 (1.5%)
SVR achieved 723 (77.7%) 323 (69.3%) 400 (86.0%) 0
Adherence (pharmacy
reﬁlls)
≤60% 115 (12.4%) 68 (14.6%) 17 (3.7%) 0
61%–79% 41 (4.4%) 35 (7.5%) 36 (7.7%)
≥80% 775 (83.2%) 363 (77.9%) 412 (88.6%) 0
Notes: p<0.05 considered signiﬁcant.
Abbreviations: HCV, hepatitis C virus; CHC, chronic hepatitis C; ETR, end-of-treatment response; NA, not available; SVR12, sustained virological response at 12 weeks
after end of treatment; UC, usual care; PC, pharmaceutical care.
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showed signiﬁcant (p=0) change in HRQoL dimensions
between the PC group and the UC group. Moreover, anxiety
was signiﬁcantly reduced (p=0.00) in the PC group (baseline
329 [70.8%] vs ﬁnal 109 [23.5%]) in comparison with the
UC group (baseline 343 [73.4%] vs ﬁnal 104 [22.3%]).
EuroQol Visual Analogue Scale
Overall, mean EQ VAS was 55.7±6.9. Baseline EQ VAS
for the UC (56.1±7.0) and PC (55.2±6.8) groups rose to
71.8±8.4 and 71.9±8.7, respectively, showing a signiﬁcant
change in both groups (p=0, Table 4)
Table 3 Drug–drug Interactions Between HCV DAAs and Concomitant Drugs
Care 
Group 
Concomitant 
Medicines (Type) 
 n (%) Sof/Rv 
(DDI,      Management) 
Sof/Dac/Rv 
(DDI,      Management) 
Dac/Rv 
(DDI,      Management) 
PC Aluminum hydroxide (Al) 3 (0.6) ■ Weak DDI,  
(2 hour gap) 
■ Weak DDI,     
(2 hour gap) 
♦  
Laxatives 1 (0.2) ♦  ♦  ♦  
Antipruritic 4 (0.9) ♦  ♦  ♦  
Multivitamins 12 (2.6) ♦  ♦  ♦  
Benzodiazepines 1 (0.2) ♦  ♦  ♦  
CV 2 (0.4) ♦  ● Amiodarone 
(alternative) 
■ Simvastatin 
(dose reduction) 
Pepzyme 1 (0.2) ♦  ♦  ♦  
No concomitant  meds 418 (89.9)       
NSAID 8 (1.7) ♦  ♦  ♦  
PPI 11 (2.4) ♦  ♦  ♦  
PPI + multivitamin 2 (0.4) ♦  ♦  ♦  
PPI + gonadotrophins 1 (0.2) ♦  ♦  ♦  
PPI + NSAID 1 (0.2) ♦  ♦  ♦  
UC Aluminium hydroxide (Al) 2 (0.4) ■ Weak DDI,  
(2 hour gap)  
■ Weak DDI,      
(2 hour gap) 
♦  
Al + PPI 2 (0.4) ■ Weak DDI,  
(2 hour gap) 
■ Weak DDI,     
(2 hour gap) 
♦  
Laxatives 2 (0.4) ♦  ♦  ♦  
Antipruritic 1 (0.2) ♦  ♦  ♦  
Multivitamins 10 (2.2) ♦  ♦  ♦  
BC+ anti-pruritic 1 (0.2) ♦  ♦  ♦  
BC+ Probiotics 1 (0.2) ♦  ♦  ♦  
Probiotics+ NSAID 1 (0.2) ♦  ♦  ♦  
CV 2 (0.4) ♦  ● Potential DDI, 
amlodipine 
●l NitrendipIne, 
atenolol 
Levothyroxine 2 (0.4) ♦  ■ Weak DDI 
(monitor TF) 
■ Weak DDI 
(monitor TF) 
Ranitidine 1 (0.2) ♦  ♦  ♦  
Hepatoprotectives 1 (0.2) ♦  ♦  ♦  
No concomitant  meds 414 (88.8)       
NSAID 6 (1.3) ♦  ♦  ♦  
PPI 14 (3.0) ♦  ♦  ♦  
PPI + laxatives 1 (0.2) ♦  ♦  ♦  
PPI + multivitamins 5 (1.1) ♦  ♦  ♦  
Notes: Colour legend adopted from EASL 2018 recommendation ).19 No clinically signiﬁcant interaction expected. Potential interaction; may require a
dosage adjustment, altered timing of administration or monitoring. These drugs should not be coadministered.
Abbreviations: PC, pharmaceutical care; UC, usual care; DAA, direct-acting antiviral; HCV, hepatitis C virus; Sof, sofosbuvir; Dac, daclatasvir; Rv, ribavirin, CV;
cardiovascular; PPI, proton-pump inhibitor; BC, Bcomplex; TF, thyroid function.
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Medication Adherence
Based on pharmacy reﬁlls, 775 (83.2%) patients had a
>80% adherence rate to the prescribed treatment, with
12.4% of patients receiving <60% of their expected reﬁlls
vs 3.7% (n=17) of patients in the PC group. Adherence
was signiﬁcantly better (>80% [p<0.001]) in the PC group
(412 [88.6%]) than the UC group (363 [77.9%], 95% CI
88.9%–91.9; Table 2).
Discussion
This study evaluated the impact of introducing a clinical
pharmacy service to HCV patients in optimizing clinical
outcomes, with an aim to improve medication adherence
and HRQoL. Viral clearance results revealed that SVR12
was achieved in 86.0% of PC-group patients and 69.3% in
the UC group. Unfortunately, as the DNA rate for SVR12
was signiﬁcantly higher in the UC group than the PC
group (28.8% vs 12.5%), it is difﬁcult to conclude the
true SVR12 rates of both groups, as a fair number of the
UC group vs the PC group (28.8% vs 12.5%) did not
appear for SVR12 follow-up. Despite the high published
SVR12 rates seen in the literature with novel DAAs,39
several factors may have contributed to the slightly
decreased SVR12 rate seen in this study: the ﬁnancial
burden to the patient from having to pay for laboratory
tests and travel costs being possible factors. An earlier
study demonstrated the burden of out-of-pocket costs
accrued by patients receiving HCV treatment.40
Interestingly, more patients (10.5%) in the UC group
experienced ADEs than the PC group (8.2%). Dyspepsia/
gastroesophageal reﬂux was the most frequent ADE (3.8%
in UC and 2.9% in PC). This low incidence of ADEs may
be attributed to the increased safety of DAAs in compar-
ison to previous regimens.41 There were 12.1% of follow-
up cases for whom interventions were required, including
49 and 38 patients who experienced ADEs in UC and PC,
respectively. Of those, 26 had signiﬁcant comorbidities.
Studies have reported that the provision of specialized
pharmacy clinical services, including medication-adminis-
tration counseling and management of ADEs, improves
patient outcomes, and in this study42,43 36 (3.9%) patients
were speciﬁcally counseled by the pharmacist to take their
concomitant medicines at different times to the HCV med-
icines. The GRUviC trial also demonstrated that a com-
prehensive pharmaceutical care programme involving
direct patient counseling before initiation of treatment
improves patient education and safety consequently.22
Our results show that HRQoL of HC patients was
signiﬁcantly improved in the PC group. According to
EQ5D scores, the three most frequent dimensions (of
moderate severity) were mobility (49.0%), pain/discomfort
(46.7%), and anxiety (70.8%). Similarly, HRQoL com-
plaints (fatigue, depression, and neurocognitive deﬁcits)
were reported by Foster et al among HCV patients.44
These results emphasize the vital role a pharmacist has
as a member of the multidisciplinary team, in improving
the QoL and disease management of patients with chronic
HCV infections. The provision of educational and suppor-
tive material in the form of counseling, adequate labeling
of medication, medication diaries, and other compliance
tools serves to facilitate adherence to routine follow-up
tests and encourages patients to take their medication as
per prescribed doses.
Table 4 Summary of EQ5D-3L Data for Health Related Quality of Life Domains
Dimensions All Patients (Reporting
Problems)
Patients Reporting Problems in UC
Level 2 (n=466)
Patients Reporting Problems in PC
Level 2 (n=465)
χ2 (p-value),
UC vs PC
Baseline,
n (%)
Final,
n (%)
Baseline,
n (%)
Final,
n (%)
χ2 (p-value)^ Baseline,
n(%)
Final,
n(%)
χ2 (p-value)^
Mobility 486 (52.2) 101 (10.8)* 240 (51.5) 55 (11.8) 20.3 (0)* 246 (52.9) 46 (9.9) 4.3 (0.38) 0.88 (0.35)
Self-care 240 (25.8) 67 (7.2)* 113 (24.2) 21 (4.5) 38.5 (0)* 127 (27.3) 24 (5.2) 12.3 (0)* 0.22 (0.64)
Usual activities 146 (15.7) 46 (4.9)* 72 (15.5) 21 (4.5) 0.023 (0.88) 74 (15.9) 25 (5.4) 2.9 (0.09)* 0.38 (0.54)
Pain/discomfort 438 (47.0) 3 (0.3)* 217 (46.6) 3 (0.6) 3.5 (0.06) 221 (47.5) 2 (0.4) 2.4 (0)* 3.00 (0.08)
Anxiety/depression 672 (72.2) 213 (22.9)* 343 (73.4) 104 (22.3) 8.4 (0.004)* 329 (70.8) 109 (23.5) 11.2 (0.001)* 0.17 (0.68)
EQ5D VAS
(Mean ± SD) 55.7±6.9 71.8±8.5 56.1±7.0 71.8±8.4 0* 55.2±6.8 71.9±8.7 0* 0*,a
Notes: p<0.05 considered signiﬁcant. at-test, *signiﬁcant value. ^McNemar χ2 showed signiﬁcant change over time. HRQoL was analyzed considering two levels of each
domain (dichotomized), ie, patients with problems and patients with no problem, wherein the two levels were used to mark the changes before treatment and after
treatment, as published elsewhere.49
Abbreviations: EQ, EuroQol; UC, usual care; PC, pharmaceutical care.
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Our study demonstrates that pharmacist-led individua-
lized patient care of HCV patients is an effective approach
that improves patient adherence when following DAA
regimens. The adherence rate was signiﬁcantly improved
>80% (p<0.001) in the PC group 412 (88.6%) over the UC
group — 363 (77.9%). Studies have shown that nonadher-
ence to combination therapy is common in routine
patients,8 and clinical trial-adherence data suggest that
SVR decreases when patients have <60% dose-interval
adherence.45 Our results are also consistent with other
interventional studies where pharmacist-led interventions
signiﬁcantly improved patient adherence to medication
regimes.25,36
This study has explored the role of the pharmacist as a
member of the health-care team in the management of
HCV. Patient data were collected from two major tertiary
hospitals with adequate sample size for the planned statis-
tical analyses. Validated and recognised data sources were
used for all information on prescription parameters and
clinical outcomes. The study is not without its limitations.
Firstly, a signiﬁcant number of patients did not attend their
SVR12 follow-up appointment, hence missing the ﬁnal
assessment by the pharmacist. Secondly, HRQoL com-
plaints may have been underreported by patients who
received treatment during their follow-up appointments.
Thirdly, this study was speciﬁc to the population served
by the tertiary-care centers, and may not be representative
of the entire patient population affected by HCV in
Pakistan. Finally, at the time of the study, DAAs were
newly approved for use in hospital B, so the recruited
subjects from this health-care facility were fewer in num-
ber. The inclusion of HBV and HDV patients would have
been of beneﬁt for improved adherence to HCV medica-
tions, but the management of these infections requires
different approaches from HCV. Some contamination
could have occurred during patients’ clinic visits and shar-
ing the same waiting area. Local validation of the transla-
tion could not be done, due to resource constraints.
This study highlights the valuable role of the pharma-
cist as part of a multidisciplinary team in the provision of
individualized care for HCV patients. It emphasises the
potential beneﬁts of adopting a collaborative-care
approach when managing HCV-infected patients at ter-
tiary-care hospitals in Pakistan. Based on our ﬁndings, it
is recommended that future research be directed toward
exploring the role of a specialist pharmacist in the man-
agement of HCV-infected patients in secondary and pri-
mary health-care settings. The development of policies to
outline the role of specialist pharmacists is something that
should be considered in Pakistan. The implementation of
such roles, which include specialist pharmacy services and
patient-centered care, in the context of LMICs is an emer-
ging concept.46,47 The management of chronic or commu-
nicable diseases, such as HCV, are potential areas where
pharmacists can play a coordinated role in achieving opti-
mum therapeutic outcomes.48 Future qualitative research
from LMICs would result in beneﬁcial additions to the
existing literature in developing clinical pharmacist roles
in LMICs.
Conclusion
This study shows that the provision of a specialist clinical
pharmacy service focused for patient-centered care is an
effective approach that would result in a positive impact
on cure rates, HRQoL, and medication adherence in the
HCV-infected population. Close monitoring of patients
contributed to the achievement of positive outcomes in
terms of goals of the therapy. This study suggests that
clinical pharmacists be incorporated into multidisciplinary
health-care team for care of HCV patients.
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